LONDON (Alliance News) - BTG PLC on Thursday said Wellstat Therapeutics Corp has secured a new drug application for Xuriden, its uridine triacetate product for the treatment of hereditary orotic aciduria.
Shares in BTG were up 1.9% to 657.50 pence on Thursday afternoon.
The FTSE 250-listed specialty pharmaceuticals company said the new drug application, accepted by the US Food and Drug Administration, is seeking approval for the drug for patients at risk of serious toxicity following an overdose of the chemotherapy agent 5-fluorouracil and patients exhibiting symptoms of serious toxicity within 96 hours of 5-FU administration.
5-fluorouracil is a key component of chemotherapy treatment and is used across a variety of solid tumours, including those in the colon, stomach, esophagus, breast, pancreas and head and neck.
Under the partnership between BTG and Wellstat, BTG will market, sell and distribute uridine triacetate for this indication in the US market.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
